On this page
- Bone Biologics Corporation
- Coffee Holding Co., Inc.
- Daqo New Energy Corp.
- ImmuCell Corporation
- Lomond Therapeutics Holdings, Inc.
- McGraw Hill, Inc.
- NightFood Holdings, Inc.
- Odyssey Health, Inc.
- Smithfield Foods, Inc.
- Springworks Therapeutics, Inc.
- STRATA Skin Sciences, Inc.
- Sunrise New Energy Co., Ltd.
- Theratechnologies Inc.
- Theriva Biologics, Inc.
- Tourmaline Bio, Inc.
Bone Biologics Corporation
At 5% or more1
Filings2
Latest filing2025-11-07
Bone Biologics Corporation has 2 Schedule 13D or 13G filings on record since 2025-07-03. 1 holder's latest filing reports 5% or more of common stock, par value $0.001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Swipe the table sideways to see every column.
Swipe the table sideways to see every column.
The latest filing names Bone Biologics Corporation, with its principal executive office as 2 Burlington Woods Drive, Ste. 100, Burlington, MA 01803 (SCHEDULE 13G/A, 2025-11-07).
Swipe the table sideways to see every column.
Coffee Holding Co., Inc.
At 5% or more1
Filings1
Latest filing2025-11-13
Coffee Holding Co., Inc. has 1 Schedule 13D or 13G filing on record since 2025-11-13. 1 holder's latest filing reports 5% or more of common stock, par value $0.001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Swipe the table sideways to see every column.
Swipe the table sideways to see every column.
The latest filing names Coffee Holding Co., Inc., with its principal executive office as 3475 VICTORY BLVD, STATEN ISLAND, NY 10314 (SCHEDULE 13G/A, 2025-11-13).
Swipe the table sideways to see every column.
Daqo New Energy Corp.
At 5% or more1
Filings1
Latest filing2025-11-13
Daqo New Energy Corp. has 1 Schedule 13D or 13G filing on record since 2025-11-13. 1 holder's latest filing reports 5% or more of ordinary shares, par value $0.0001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Swipe the table sideways to see every column.
Swipe the table sideways to see every column.
The latest filing names Daqo New Energy Corp., with its principal executive office as 666 LONGDU AVENUE, WANZHOU, CHONGQING (SCHEDULE 13G/A, 2025-11-13).
The following percentages are based on 333,759,632 Shares outstanding, which is the total number of Shares outstanding as of December 31, 2024, as disclosed in the Issuer's Annual Report on Form 20-F filed with the Securities and Exchange Commission on April 29, 2025.Gorzynski Michael, SCHEDULE 13G/A, 2025-11-13
Swipe the table sideways to see every column.
ImmuCell Corporation
At 5% or more1
Filings1
Latest filing2025-11-20
ImmuCell Corporation has 1 Schedule 13D or 13G filing on record since 2025-11-20. 1 holder's latest filing reports 5% or more of common stock, $0.10 par value per share. Each figure below is the holder's own, as filed, with the filing linked.
Swipe the table sideways to see every column.
Swipe the table sideways to see every column.
The latest filing identifies ImmuCell Corporation by CUSIP 045252306 and gives its principal executive office as 56 Evergreen Drive, Portland, ME 04103 (SCHEDULE 13D/A, 2025-11-20).
The source of the approximately $2,293,750 used in connection with the compulsory redemption of the limited partners of Craton Capital, LP ("Craton") pursuant to previously agreed upon terms, was general investment funds.Ejnar A. Knudsen III, SCHEDULE 13D/A, 2025-11-20
Ejnar A. Knudsen III
All shares held by the Reporting Person are held by the Reporting Person for investment purposes.
The Reporting Person currently has no plans or proposals that relate to, or would result in, any of the matters described in subsections (a) through (j) of Item 4 of the instructions to Schedule 13D.Item 4 of the SCHEDULE 13D/A filed 2025-11-20
Swipe the table sideways to see every column.
Swipe the table sideways to see every column.
Lomond Therapeutics Holdings, Inc.
At 5% or more1
Filings1
Latest filing2025-11-13
Lomond Therapeutics Holdings, Inc. has 1 Schedule 13D or 13G filing on record since 2025-11-13. 1 holder's latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.
Swipe the table sideways to see every column.
Swipe the table sideways to see every column.
The latest filing names Lomond Therapeutics Holdings, Inc., with its principal executive office as 8 The Green Ste 8490, Dover, DE 19901 (SCHEDULE 13G/A, 2025-11-13).
Swipe the table sideways to see every column.
Swipe the table sideways to see every column.
McGraw Hill, Inc.
At 5% or more1
Filings1
Latest filing2025-11-13
McGraw Hill, Inc. has 1 Schedule 13D or 13G filing on record since 2025-11-13. 1 holder's latest filing reports 5% or more of common stock, par value $0.01. Each figure below is the holder's own, as filed, with the filing linked.
Swipe the table sideways to see every column.
Swipe the table sideways to see every column.
The latest filing names McGraw Hill, Inc., with its principal executive office as 8787 Orion Place, Columbus, OH 43240 (SCHEDULE 13G, 2025-11-13).
Swipe the table sideways to see every column.
Swipe the table sideways to see every column.
NightFood Holdings, Inc.
At 5% or more1
Filings1
Latest filing2025-11-18
NightFood Holdings, Inc. has 1 Schedule 13D or 13G filing on record since 2025-11-18. 1 holder's latest filing reports 5% or more of common. Each figure below is the holder's own, as filed, with the filing linked.
Swipe the table sideways to see every column.
Swipe the table sideways to see every column.
The latest filing names NightFood Holdings, Inc., with its principal executive office as 500 White Planes Road, Suite 520, Tarrytown, NY 10591 (SCHEDULE 13G, 2025-11-18).
Swipe the table sideways to see every column.
Swipe the table sideways to see every column.
Odyssey Health, Inc.
At 5% or more1
Filings1
Latest filing2025-11-21
Odyssey Health, Inc. has 1 Schedule 13D or 13G filing on record since 2025-11-21. 1 holder's latest filing reports 5% or more of odyy - common stock, par value $0.001. Each figure below is the holder's own, as filed, with the filing linked.
Swipe the table sideways to see every column.
Swipe the table sideways to see every column.
The latest filing names Odyssey Health, Inc., with its principal executive office as 2300 West Sahara Avenue, Suite 800 - #4012, Las Vegas, CA 89102 (SCHEDULE 13G/A, 2025-11-21).
Swipe the table sideways to see every column.
Smithfield Foods, Inc.
At 5% or more1
Filings1
Latest filing2025-11-12
Smithfield Foods, Inc. has 1 Schedule 13D or 13G filing on record since 2025-11-12. 1 holder's latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.
Swipe the table sideways to see every column.
Swipe the table sideways to see every column.
The latest filing names Smithfield Foods, Inc., with its principal executive office as 200 Commerce Street, Smithfield, VA 23430 (SCHEDULE 13G/A, 2025-11-12).
87.0%, calculated based on a total of 393,112,711 shares of Common Stock outstanding as of October 27, 2025, as reported in the Issuer's quarterly report on Form 10-Q filed with the Securities and Exchange Commission on October 28, 2025.WH Group Limited, SCHEDULE 13G/A, 2025-11-12
Swipe the table sideways to see every column.
Swipe the table sideways to see every column.
Springworks Therapeutics, Inc.
At 5% or more1
Filings4
Latest filing2025-11-12
Springworks Therapeutics, Inc. has 4 Schedule 13D or 13G filings on record since 2025-07-07. 1 holder's latest filing reports 5% or more of common stock, par value $.0001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Swipe the table sideways to see every column.
Swipe the table sideways to see every column.
The latest filing names Springworks Therapeutics, Inc., with its principal executive office as 100 WASHINGTON BOULEVARD, STAMFORD (SCHEDULE 13G/A, 2025-11-12).
Swipe the table sideways to see every column.
STRATA Skin Sciences, Inc.
At 5% or more2
Filings4
Latest filing2025-11-07
STRATA Skin Sciences, Inc. has 4 Schedule 13D or 13G filings on record since 2025-09-04. 2 holders' latest filing reports 5% or more of common stock, $0.001 par value per share. Each figure below is the holder's own, as filed, with the filing linked.
Swipe the table sideways to see every column.
Swipe the table sideways to see every column.
The latest filing names STRATA Skin Sciences, Inc., with its principal executive office as 5 Walnut Grove Drive, Suite 140, Horsham, PA 19044 (SCHEDULE 13G/A, 2025-11-07).
Swipe the table sideways to see every column.
Sunrise New Energy Co., Ltd.
At 5% or more1
Filings1
Latest filing2025-11-20
Sunrise New Energy Co., Ltd. has 1 Schedule 13D or 13G filing on record since 2025-11-20. 1 holder's latest filing reports 5% or more of ordinary shares. Each figure below is the holder's own, as filed, with the filing linked.
Swipe the table sideways to see every column.
Swipe the table sideways to see every column.
The latest filing names Sunrise New Energy Co., Ltd., with its principal executive office as R703 W R&D BLDG,ZIBO SCIENCE & TECH PARK, NO. 69 SANYING ROAD ZHANGDIAN DISTRICT, ZIBO CITY, SHANDONG PROVINCE (SCHEDULE 13G, 2025-11-20).
Swipe the table sideways to see every column.
Swipe the table sideways to see every column.
Theratechnologies Inc.
At 5% or more1
Filings4
Latest filing2025-11-14
Theratechnologies Inc. has 4 Schedule 13D or 13G filings on record since 2025-07-29. 1 holder's latest filing reports 5% or more of common shares. Each figure below is the holder's own, as filed, with the filing linked.
Swipe the table sideways to see every column.
Swipe the table sideways to see every column.
The latest filing names Theratechnologies Inc., with its principal executive office as 2015 Peel Street, Suite 1100, Montreal (SCHEDULE 13G/A, 2025-11-14).
Swipe the table sideways to see every column.
Theriva Biologics, Inc.
At 5% or more1
Filings3
Latest filing2025-11-10
Theriva Biologics, Inc. has 3 Schedule 13D or 13G filings on record since 2025-07-31. 1 holder's latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.
Layoffs on record: 1 filing or notice, latest 2025-10-02 (layoff filings and notices).
Swipe the table sideways to see every column.
Swipe the table sideways to see every column.
The latest filing names Theriva Biologics, Inc., with its principal executive office as 9605 MEDICAL CENTER DRIVE, SUITE 270, ROCKVILLE, MD 20850 (SCHEDULE 13G, 2025-11-10).
Swipe the table sideways to see every column.
Swipe the table sideways to see every column.
Tourmaline Bio, Inc.
At 5% or more3
Filings4
Latest filing2025-11-14
Tourmaline Bio, Inc. has 4 Schedule 13D or 13G filings on record since 2025-08-14. 3 holders' latest filing reports 5% or more of common stock, par value $0.0001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Swipe the table sideways to see every column.
Swipe the table sideways to see every column.
The latest filing names Tourmaline Bio, Inc., with its principal executive office as 27 WEST 24TH STREET, SUITE 702, NEW YORK, NY 10010 (SCHEDULE 13G/A, 2025-11-14).
Swipe the table sideways to see every column.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.
All 5%+ stakes
